Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Valeant Pharmaceuticals Intl Inc    VRX   CA91911K1021

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Valeant Pharmaceuticals Intl : Health Care Higher As Paulson Joins Valeant Board - Health Care Roundup

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/19/2017 | 10:31pm CEST

Shares of health-care companies rose as one big investor endorsed one of the hardest hit companies during the recent retreat from the sector. Hedge-fund billionaire John Paulson joined the board of Valeant Pharmaceuticals International, a sign that the investor remains bullish on the drugmaker's prospects despite the rout in Valeant's shares over the last year. The specialty drugmaker came under pressure after allegations of accounting improprieties and lost the support of some big institutional holders, such as William Ackman's Pershing Square. Medical-test maker PerkinElmer said it would buy a German medical-diagnostics company Euroimmun Medical Laboratory Diagnostics for $1.3 billion, expanding its reach into autoimmune and allergy testing.

-Rob Curran, rob.curran@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALEANT PHARMACEUTICALS IN
08/21 VALEANT PHARMACEUTICALS INTL : (VRX) Turnaround Forges Ahead
08/21 VALEANT PHARMACEUTICALS INTL INC : Today's Research Reports on Stocks to Watch: ..
08/17 VALEANT PHARMACEUTICALS INTL : Paulson & Co., Inc. Reiterates Confidence In Vale..
08/17 VALEANT PHARMACEUTICALS INTL : Receives Complete Response Letter from the FDA fo..
08/17 BIOTECH MOVERS : Valeant Pharmaceuticals International, Inc. (NYSE:VRX), Aerie P..
08/16 VALEANT PHARMACEUTICALS INTL : Receives FDA Confirmation Of Voluntary Action Ind..
08/10 JOHN PAULSON : Hedge fund Paulson & Co trims stake in Valeant
08/10 VALEANT PHARMACEUTICALS INTL : Paulson & Co., Inc. Reiterates Confidence In Vale..
08/09 VALEANT PHARMACEUTICALS INTL : Press Release concerning latanoprostene bunod oph..
08/09 VALEANT PHARMACEUTICALS INTL : Receives Complete Response Letter from the FDA fo..
More news
Financials ($)
Sales 2017 8 701 M
EBIT 2017 3 283 M
Net income 2017 -583 M
Debt 2017 25 886 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 3,54x
EV / Sales 2018 3,36x
Capitalization 4 912 M
Chart VALEANT PHARMACEUTICALS IN
Duration : Period :
Valeant Pharmaceuticals In Technical Analysis Chart | VRX | CA91911K1021 | 4-Traders
Technical analysis trends VALEANT PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 18
Average target price 16,1 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive VP-Finance
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert Alexander Ingram Director
Robert N. Power Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VALEANT PHARMACEUTICALS INTL INC-2.62%4 912
JOHNSON & JOHNSON15.83%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.86%194 554
MERCK AND COMPANY5.27%167 705